

DENNEMEYER & CO LTD

Regent House Heaton Lane
Stockport Cheshire
England SK4 1BB

Tel: 0161-477 2567
Fax No: 0161-429 8063
gilliang@denpat.uk.com

RECEIVED

JUN 17 2010

OFFICE OF PETITIONS

Commissioner of Patents and Trademarks
Box M. FEE
WASHINGTON DC 20231
U S A

Attn: Ms. Dorethea Allen

Monday, 14 June 2010

Re: **Patent 7022731 (serial number 10/759396)**
1st maintenance fee due on 4 October 2010

Deposit Account 04-0750
Additional payment

Dear Ms Allen

Reference is made to our 04th year fee payment of \$ 490.00 on 1 October 2009.We have now been advised by our client that **LARGE entity status applies.**We, therefore, would like to request you to take an additional payment in the amount of \$ **490.00** plus any additional charges from our deposit account number 04-0750.

Enclosed, we are sending a copy of a declaration from the Assignee confirming a large entity status. We kindly ask you to update your record accordingly.

We thank you in advance for your assistance and remain.

Very yours truly
Dennemeyer & Co Stockport
Payor Number: 287

06/16/2010 MBANGURA 00000006 040750 7022731

01 FC:1559 490.00 DA

Mrs Gillian Gascoigne

**PORTOLA**

Pharmaceuticals, Inc.

info@portola.com

www.portola.com

T: 650.246.7000

F: 650.246.7376

270 East Grand Avenue

South San Francisco, CA 94080

Innovative Science. Patient Focused.

RECEIVED

JUN 17 2010

OFFICE OF PETITIONS

LETTER OF ASSERTION

June 10, 2010

Director of the U.S. Patent and Trademark Office
Attn: Maintenance Fees
2051 Jamieson Avenue, Suite 300
Alexandria, VA 22314

- Re.: (1) U.S. Patent No. 7,109,332, Issued 09/19/2006
Applicant: Portola Pharmaceuticals, Inc.
Atty. Docket No.: 022104-000510US
Portola Docket No. PTL001510US
- (2) U.S. Patent No. 7,022,731, Issued 04/04/2006
Applicant: Portola Pharmaceuticals, Inc.
Atty. Docket No.: 022104-000232US
Portola Docket No. PTL001212US
- (3) U.S. Patent No. 7,056,926, Issued 06/09/2006
Applicant: Portola Pharmaceuticals, Inc.
Atty. Docket No.: 022104-000241US
Portola Docket No. PTL001221US
- (4) U.S. Patent No. 7,205,296, Issued 04/17/2007
Applicant: Portola Pharmaceuticals, Inc.
Atty. Docket No.: 022104-001510US
Portola Docket No. PTL002110US

TO WHOM IT MAY CONCERN:

We hereby declare that **Portola Pharmaceuticals, Inc.** is the assignee of above-referenced U.S. patents (1) – (4). In regards to those patents, Portola Pharmaceuticals, Inc. has lost entitlement to small entity status according to the USPTO standard.

We hereby declare that Patent Nos. 7,109,332; 7,022,731; 7,056,926; and 7,205,296 have been licensed to **Novartis Pharma AG** which is a large entity according to the USPTO standard.

**PORTOLA**

info@portola.com | T: 650.246.7800 | 270 East Grand Avenue
www.portola.com | F: 650.246.7376 | South San Francisco, CA 94080

Innovative Science. Patient Focused.

Director of the U.S. Patent and Trademark Office

June 10, 2010

Page 2

We request that the maintenance fees be paid at the large entity tariff.

Sincerely,

William D. Lis
Chief Executive Officer
Portola Pharmaceuticals, Inc.